bioRxivCancer BiologyPreprint
Unbiased Assessment of H-STS cells as high-fidelity models for gastro-enteropancreatic neuroendocrine tumor drug mechanism of action analysis
M. J. Alvarez, P. Yan, M. L. Alpaugh, M. Bowden, E. Sicinska, C. W. Zhou, C. Karan, R. B. Realubit, P. S. Mundi, A. Grunn, D. Jäger, J. A. Chabot, A. T. Fojo, P. E. Oberstein, H. Hibshoosh, J. W. Milsom, M. H. Kulke, M. Loda, G. Chiosis, D. L. Reidy-Lagunes, A. Califano
Abstract
Quantitative metrics to objectively assess the fidelity of cancer models, such as cell lines, organoids, or patient-derived xenografts (PDXs), remain elusive, with histological criteria or the presence of specific mutations often used as driving principles. We show that molecular criteria, based on the regulatory proteins responsible for maintaining transcriptional cell state and its regulatory network, are effective in identifying models that can recapitulate drug mechanism of action and drug sensitivity, independent of histological consideration.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- research focus: cell type annotation
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Evaluating the transcriptional fidelity of cancer models
Da Peng, Rachel Gleyzer, … Patrick Cahan·Genome MedicinePeer-reviewed·Apr 29, 2021
- Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient In Vivo Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted 177Lu-DOTATATE
Rupali Sharma, Bhargav Earla, … Samira Mercedes Sadowski·bioRxiv·Apr 25, 2022
- Genomic and single-cell characterization of patient-derived tumor organoid models of head and neck squamous cell carcinoma
Jung Hyun Um, Yueyuan Zheng, … De‐Chen Lin·Cancer ResearchPeer-reviewed·Apr 22, 2025
- Integrated Patient-Derived Xenograft and Patient-Derived Cell Models Reveal Therapeutic Vulnerabilities Beyond Standard-of-Care Therapy in Endometrial Cancer
Tianyue Li, Fang Huang, … Shujie Yang·bioRxiv·Jul 27, 2026
- A Novel Humanized Immune Stroma PDX Cancer Model for Therapeutic Studies
D. Yang, I. Beddows, … R. Buckanovich·bioRxiv·Jul 3, 2023
- Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer PDXs
Umberto Perron, Elena Grassi, … Francesco Iorio·Nature CommunicationsPeer-reviewed·Nov 11, 2024